In India, over 10 million people suffer from Hepatitis C which was previously believed that it was not curable.
This condition challenged Pharma companies all over the world in the discovery of medicine to effectively treat Hepatitis C. They’ve been investing time and money for the research.
Today, ZydusCadila a drug firm launched a generic version of Gilead Sciences’ Hepatitis C drug Sofosbuvir in India under the brand name ‘SoviHep’. They had signed a non-exclusive licensing agreement which will allow the manufacture of sofosbuvir and the dosage combination of ledipasvir/sofosbuvir for distribution in 91 countries including India. (Read: Now oral medication to treat Hepatitis C on the horizon)
The company said that ZydusHeptiza will be responsible for the marketing of this medicine, which has a complete basket of brands for Hepatitis B and C. The addition of SoviHep aims to complete this critical care portfolio. (Read: Gilead expands hepatitis C licensing pacts with Indian firms)
Pharmabiz, Pankaj R Patel, chairman and managing director of the Zydus group, said that better therapy outcomes and improved quality of life has been made possible due to innovations in healthcare. He further notified that they were glad to partner with Gilead Sciences to make this breakthrough therapy accessible to patients with hepatitis C in India at affordable prices. This new breakthrough bridges the gap between people and their healthcare needs. (Read: Gilead’s licensing agreement to increase accessibility of hepatitis C drug)
Hepatitis C is an infectious disease affecting the liver, caused by the virus know as HCV and is spread primarily by blood-to-blood contact, poorly sterilized medical equipment and transfusions. Sexual transmission is also possible, but is less common. No vaccine available against HCV.
Treatment for hepatitis C usually involves:
- Oral medications and injections: A combination of oral medications (antiviral drugs) and injections are used to fight the viruses. Treatment may also involve the use of other drugs to counteract the drop in blood cell counts that occur due to the hepatitis C drug.
- Liver transplantation: This is a viable treatment option for end-stage liver disease and acute liver.
This new cost-effective drug aims to Indian population and to improve the condition across the country.